Adverse event reporting is a key component of: Response:

Question

Options

• AMarket research studies
• BProduct development phases
• CPost-marketing surveillance
• DInitial drug discovery processes

• A
  15% (4)
• B
  7% (2)
• C
  74% (20)
• D
  4% (1)

Explanation

Post-marketing surveillance (C) is correct because it encompasses all activities that monitor a drug or medical product's safety after it has been approved and released to the general public - and adverse event reporting is the primary mechanism for detecting unexpected harms in real-world use that clinical trials may have missed.

Why the distractors are wrong:

• A (Market research studies) focuses on consumer preferences, market size, and competitive positioning - not safety monitoring.
• B (Product development phases) involves designing and testing a product pre-approval; safety data is collected here, but formal adverse event reporting systems are a regulatory/post-approval construct.
• D (Initial drug discovery) is early-stage lab and computational work identifying drug candidates - far too early for any human adverse event data.

Memory tip: Think "after the launch, watch the damage" - post-marketing = post-launch, and adverse events are the "damage" you're watching for. The acronym FAERS (FDA Adverse Event Reporting System) only applies to marketed drugs, reinforcing the link to post-marketing surveillance.

No community discussion yet for this question.